Search results for: NICE

Foundation

…below a pre-established threshold. In the UK, this threshold is typically between £20,000-£30,000 (although there are exceptions) and is set by the National Institute for Health and Care Excellence (NICE)….

OHE in the BMJ: Reforming the Cancer Drug Fund, and Reviving the PROMs Programme

10 December 2014

…for prioritising access to it “will continue to undermine NICE, duplicate effort, and distort allocation of NHS resources while failing to support the development of cost effective drugs from which…

OHE at ISPOR Philadelphia: Presentations and Posters

4 June 2015

…large prevalence diseases? Lessons from hepatitis C – Adrian Towse’s slides Early access to medicines: What is in it for payers? – Adrian Towse’s slides An Analysis of NICE ‘Recommended…

OHE Lunchtime Seminar on 14 December 2015: From the Antipodes to the Motherland: Reflections on HTA Decision Makers as Budget Takers and Budget Makers

13 November 2015

…decision-making criteria employed by health technology assessment (HTA) agencies differs between countries. Specifically, while the National Institute for Health and Care Excellence (NICE), the Australian Pharmaceutical Benefits Advisory Committee (PBAC)…

OHE and ABPI Webinar: New EQ-5D-5L value sets for England and the UK and Implications for HTA

11 July 2016

…instrument recommended by the National Institute for Health and Care Excellence (NICE) for use in estimating Quality Adjusted Life Years (QALYs) in cost effectiveness analysis. It is accompanied by a…

OHE at ISPOR Europe 2016: Risk-sharing, Differential Pricing, the Cancer Drugs Fund, and Patient Reported Outcomes

26 October 2016

…Excellence (NICE) and were not routinely available within the NHS in England. After a consultation process, it was agreed that from July 2016, NICE will appraise all new  licenced cancer…

25 Years of the Cost Effectiveness Acceptability Curve

30 December 2019

…25 years. She noted that “the substantial impact of the paper is also clear from its inclusion in methods guidelines, including NICE’s methods for technology assessment and in the recommendations…

The Expanding Value Footprint of Oncology Treatments

1 May 2014

…treatment regimen, or patient population or subpopulation. The decisions of three entities were included in the study: the Haute Autorité de Santé (HAS) in France, NICE in England and Wales,…

Incorporating Multiple Criteria in HTA: Methods and Processes

1 March 2011

…such decisions, by NICE in the UK and by similar bodies elsewhere. Other… What a health care system should pay for depends, of course, on the health gain that results….